Unlicensed Medicines Demand IPS Pharma specializes in unlicensed medicines, specials, and investigational products, offering extensive formulation capabilities and a global supplier network. This positions them to support clinics and patients needing tailored therapies or IMPs for trials, presenting opportunities to expand unlicensed product offerings and rev share with healthcare providers.

Clinical Trial Support With capabilities to supply over 20,000 formulations for unlicensed medicines and trial comparators from a MHRA-licensed facility, IPS Pharma can attract CROs and pharma sponsors seeking reliable sourcing, regulatory compliance, and timely delivery for multi-site or international studies.

Strategic Partnerships Recent partnerships, such as with Dunbar Pharma and Avicanna, demonstrate momentum in expanding API and distribution capabilities. Targeting similar partners or co-development opportunities could broaden IPS Pharma’s product pages and geographic reach in unlicensed and specialty medicines.

Regional Expansion Headquartered in Surrey with an international scope, IPS Pharma’s presence and MHRA licensing support growth in the UK and European markets for unlicensed products, trial supplies, and special obtains, suggesting proactive sales efforts toward regional hospitals, clinics, and research institutions.

Value Proposition The emphasis on ethical standards, rapid delivery, patient-centric solutions, and a robust supplier network creates a compelling selling point for healthcare buyers requiring compliant, high-quality unlicensed medicines and trial materials, alongside scalable manufacturing and sourcing capabilities.